Podcast
Alex Oshmyansky, MD, PhD, CEO / Co-Founder
S2 Episode 4 of BioByteas by Windsor Bux welcomes Alex Oshmyansky, MD, PhD, CEO / Co-Founder
Alex Oshmyansky, CEO and founder of the Mark Cuban Cost plus drug pharmacy company, discusses his journey in creating a public benefit corporation to manufacture and sell affordable medicines. He shares his motivation for starting the company, which stemmed from witnessing patients in the US being unable to afford their medications and experiencing the high cost of generic drugs. Alex talks about the challenges of disrupting the pharmaceutical industry and the complex drug supply chain in the US. He emphasizes the importance of transparency in pricing and the need for solutions that allow biotech companies to access the market without relying on large purchasing conglomerates.
Takeaways
- Creating a public benefit corporation can help manufacture and sell affordable medicines
- The complex drug supply chain in the US contributes to high drug prices
- Transparency in pricing is crucial for reducing costs and ensuring fair access to medications
- There is a need for solutions that allow biotech companies to access the market without relying on large purchasing conglomerates
You can also listen to this podcast on Spotify:
Welcome to BioBytes – Windsor Bux, where we bring you exclusive interviews with the movers and shakers of the biotech and pharmaceutical industry. Join us as we delve into the experiences and valuable insights of leading executives, exploring how they’re shaping the future and making a difference. Get ready for compelling conversations that will expand your knowledge and inspire your own journey in this exciting field!
- Shehnaaz Suliman, M.D, CEO at ReCode Therapeutics
- Sandy Milligan, MD JD, C-Suite Executive & Board Member
- Alex Oshmyansky, MD, PhD, CEO / Co-Founder
- Derek Adams, CEO & President
- Jason Cole – CEO & Chair of the Board, SalioGen
- David Donabedian, PhD – Executive Partner, Interim NewCo CEO, Longwood Fund
- Stephanie Oestreich, PhD, MPA Managing Director at Myeloma Investment Fund
- Ronan O’Hagan, Chief Executive Officer
- Alison Schecter, MD, CMO/CEO
- Joe Foster – Reebok, Founder